Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.4.2167

Lung Cancer Detection by Screening - Presenting Circulating miRNAs as a Promising Next Generation Biomarker Breakthrough  

Ramshankar, Vijayalakshmi (Preventive Oncology, Cancer Institute (WIA))
Krishnamurthy, Arvind (Surgical Oncology, Cancer Institute (WIA))
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.4, 2013 , pp. 2167-2172 More about this Journal
Abstract
Lung cancer remains a major cause of morbidity and mortality worldwide, accounting for more deaths than any other cause. All the clinical practice guidelines recommended against routine screening for lung cancer have cited lack of robust evidence, at least until a few years back. However, the potential to screen lung cancers has received renewed interest due to superior performance of low dose CT (LD-CT) in detecting early stage cancers. The incremental costs and risks involved due to the invasive procedures in the screened population due to a high false positivity rate questions the use of LD-CT scan as a reliable community based screening tool. There is therefore an urgent need to find a less invasive and a more reliable biomarker that is crucial to increase the probability of early lung cancer detection. This can truly make a difference in lung cancer survival and at the same time be more cost and resource utilization effective. Sampling blood serum being minimally invasive, low risk and providing an easy to obtain biofluid, needs to be explored for potential biomarkers. This review discusses the use of circulatory miRNAs that have been able to discriminate lung cancer patients from disease free controls. Several studies conducted recently suggest that circulating miRNAs may have promising future applications for screening and early detection of lung cancer.
Keywords
Lung cancer screening; circulating miRNA; early stage lung cancers; plasma miRNA; serum miRNA;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Aberle DR, Adams AM, Berg CD, et al (2011). National lung screening trial research team reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 365, 395-409.   DOI   ScienceOn
2 Adriano MP, Sandro MP, Matteo Giaj-Levra, et al (2012). Clinical implications and added costs of incidental findings in an early detection study of lung cancer by using lowdose spiral computed tomography. Clinical Lung Cancer, 14, 139-48.
3 Avila-Moreno F, Urrea F, Ortiz-Quintero B (2011). MicroRNAs in diagnosis and prognosis in lung cancer. Rev Invest Clin, 63, 516-35.
4 Bach PB, Jett JR, Pastorino U, et al (2007). Tockman MS, Swensen SJ, Begg CB: computed tomography screening and lung cancer, JAMA, 297, 953-61.   DOI   ScienceOn
5 Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33.   DOI   ScienceOn
6 Bellomi M, Rampinelli C, Funicelli L, Veronesi G (2006). Screening for lung cancer. Cancer Imaging, 6, 9-12.   DOI
7 Bianch F, Nicassio1y F, Marzi1 M, et al (2011). A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Med, 3, 495-503.   DOI
8 Boeri M, Verri C, Conte D, et al (2011). MicroRNA signatures in tissues and cancer. Cancer Imaging, 6, 9-12.
9 Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.   DOI   ScienceOn
10 Iorio MV, Croce CM (2009). MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol, 27, 5848-56.   DOI   ScienceOn
11 Jemal A, Bray F, Melissa M, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
12 Kaneko M, Eguchi K, Ohmatsu H, et al (1996). Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology, 201, 798-802.   DOI
13 Keller A, Leidinger P, Gislefoss R, et al (2011). Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA biology, 8, 506-16.   DOI
14 Kloosterman WP, Plasterk RH (2006). The diverse functions of microRNAs in animal development and disease. Dev Cell, 11, 441-50.   DOI   ScienceOn
15 Krishnamurthy A, Vijayalakshmi R, Gadigi V, et al (2012). The relevance of non-smoking associated lung cancer in India: A Single centre experience. Ind J Cancer, 49, 82-8.   DOI
16 Le HB, Zhu WY, Chen DD, et al (2012). Evaluation of dynamic change of serum miR-21 and miR-24 in pre-and postoperative lung carcinoma patients. Med Oncol, 29, 3190-7.   DOI   ScienceOn
17 Miettinen OS (2000). Screening for lung cancer: can it be costeffective? CMAJ, 162, 1431-6.
18 Mitchell PS, Parkin RK, Kroh EM, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 105, 10513-8.   DOI   ScienceOn
19 Ou SH, Ziogas A, Zell JA (2009). Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol, 4, 37-43.   DOI   ScienceOn
20 Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006.   DOI   ScienceOn
21 Cortez MA, Calin GA (2009). MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther, 9, 703-711   DOI
22 Crowell RE, Goetz T, Wiggins C, et al (2007). Regional disparities in treatment and survival of early stage non-small cell lung cancer. Ethn Dis, 17, 358-64.
23 Deiderich S, Lentschig, Overbeck, et al (2001). Detection of pulomonary nodules at spiral CT: comparison of maximum intensity projection sliding slabs and single image reporting. Eur J Radiol 11, 1345-50. detected lung cancer. Proc Natl Acad Sci USA, 108, 3713-8.   DOI   ScienceOn
24 Foss KM, Sima C, Ugolini D, et al (2011). miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol, 6, 482-8.   DOI
25 Heneghan HM, Miller N, Kerin MJ (2010). Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol, 28, 573-4.   DOI
26 Hennessey PT, Sanford T, Choudhary A, et al (2012). Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One, 7, 32307.   DOI
27 Henschke CI, Yankelevitz DF, Libby DM (2006). Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med, 355, 1763-71.   DOI   ScienceOn
28 Henschke CI, Yip R, Yankelevitz DF, Miettinen OS (2006). Computed tomography screening for lung cancer : prospects of surviving competing causes of death. Clin Lung Cancer, 7, 323-5.   DOI   ScienceOn
29 Hu Z, Chen X, Zhao Y (2010). Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol, 28, 1721-6.   DOI   ScienceOn
30 Rabinowits G, Gercel-Taylor C, Day JM, et al (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer, 10, 42-6.   DOI   ScienceOn
31 Shen J, Todd NW, Zhang H, et al (2011) Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest, 91, 579-87.   DOI   ScienceOn
32 Sone S, Li F, Yang ZG, et al (2001). Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer, 84, 25-32   DOI   ScienceOn
33 Sone S, Takashima S, Li F, et al (1998). Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet, 351, 1242-5.   DOI   ScienceOn
34 Stefani G, Slack FJ (2008). Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol, 9, 219-30.   DOI   ScienceOn
35 Swaminathan R, Shantha V, Ferley J, et al (2011). Trends in cancer incidence in Chennai city (1982-2006) and statewide predictions of future burden in Tamilnadu (2007-16). Nat Med J India, 24, 72-7.
36 Tsujiura M, Ichikawa D, Komatsu S, et al (2010). Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer, 102, 1174-9.   DOI   ScienceOn
37 Vasudevan S, Tong Y, Steitz JA (2007). Switching from repression to activation: microRNAs can up-regulate translation. Science, 318, 1931-4.   DOI   ScienceOn
38 Wei J, Gao W, Zhu CJ, et al (2011). Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer, 30, 407-14.   DOI
39 Welch HG, Black WC (2010). Overdiagnosis in cancer. J Natl Cancer Inst, 102, 605-13.   DOI   ScienceOn
40 Welch HG, Woloshin S, Schwartz LM, et al (2007). Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med, 167, 2289-95.   DOI   ScienceOn
41 Wiener RS, Schwartz LM, Woloshin S, et al (2011). Populationbased risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med, 155, 137-44.   DOI   ScienceOn
42 Xie Y, Todd NW, Liu Z (2010). Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer, 67, 170-6.   DOI   ScienceOn
43 Xu P, Guo M, Hay BA (2004). MicroRNAs and the regulation of cell death. Trends Genet, 20, 617-24.   DOI   ScienceOn
44 Yuxia M, Zhennan T, Wei Z (2012). Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol, 138, 2045-50.   DOI   ScienceOn
45 Zheng D, Haddadin S, Yong Wang (2011). Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol, 4, 575-86.